Home>>Signaling Pathways>> Apoptosis>> Other Apoptosis>>PD-1/PD-L1 inhibitor 1 (BMS-1)

PD-1/PD-L1 inhibitor 1 (BMS-1) (Synonyms: BMS-1, Programmed Cell Death 1/Programmed Cell Death-Ligand 1 Inhibitor 1)

Catalog No.GC15142

PD-1/PD-L1 inhibitor 1 (BMS-1) is an inhibitor of the PD-1/PD-L1 protein/protein interaction (IC50 between 6 and 100 nM).

Products are for research use only. Not for human use. We do not sell to patients.

PD-1/PD-L1 inhibitor 1 (BMS-1) Chemical Structure

Cas No.: 1675201-83-8

Size Price Stock Qty
10mM (in 1mL DMSO)
$123.00
In stock
5mg
$111.00
In stock
10mg
$176.00
In stock
25mg
$352.00
In stock
50mg
$510.00
In stock
100mg
$816.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Product Documents

Quality Control & SDS

View current batch:

Protocol

Cell experiment [1]:

Cell lines

mouse alveolar macrophage cell line(MH-S)

Preparation Method

MH-S cells were subcultured for three times and divided into control group, lipopolysaccharide(LPS) group and LPS+ PD-1/PD-L1 inhibitor 1 (BMS-1) group. The control group was given RPMI-1640 medium equal to LPS group and LPS+BMS-1 group. When the cells in LPS group and LPS+BMS-1 group grew to 70-80% fusion, 10 ng/ml lipopolysaccharide at 37 ˚ stimulate in 5% CO2 humidified atmosphere at C for 24 hours, and then treat with 1 µ mol/L PD-1/PD-L1 inhibitor 1 (BMS-1) at 37 ° C for 72 hours.

Reaction Conditions

1 µmol/L PD-1/PD-L1 inhibitor 1

Applications

PD-1/PD-L1 inhibitor 1 treatment attenuated apoptosis induced by LPS exposure. The results showed that after LPS stimulation, alveolar macrophages showed a high level of PD-1 expression and increased apoptosis. After treatment with PD-1/PD-L1 inhibitor, PD-1 expression and alveolar macrophage apoptosis decreased.

References:

[1]. Jia L, Liu K, Fei T, et al. Programmed cell death‑1/programmed cell death‑ligand 1 inhibitors exert antiapoptosis and antiinflammatory activity in lipopolysaccharide stimulated murine alveolar macrophages[J]. Experimental and Therapeutic Medicine, 2021, 21(4): 1-7.

Background

PD-1/PD-L1 inhibitor 1 is a PD-1/PD-L1 interaction inhibitor with an IC50 value between 6 and 100 nM[1]. PD-1 / PD-L1 regulates cell signaling pathways and epigenetic modifications, thereby inhibiting T cell and B cell proliferation and effector functions. Lack of tumor antigen and effective antigen presentation, abnormal activation of carcinogenic pathway, IFN- γ Signal mutation, immunosuppressive tumor microenvironment (such as regulatory T cells, myeloid derived inhibitory cells, M2 macrophages, and immunosuppressive cytokines) can lead to resistance to PD-1 / PD-L1 blockade.

PD-1/PD-L1 inhibitor 1 has been identified to be a potent and selective small molecule inhibitor blocking the interaction of programmed cell death protein 1 (PD-1) with its ligand protein (PD-L1) [3]. PD-1/PD-L1 inhibitor 1 was also found to act as an immunomodulator. In preclinical studies, PD-1/PD-L1 inhibitor 1 was able to block PD-1/PD-Ll interactions with an IC50 value between 6 and 100 nM, which was measured by a homogenous time-resolved fluorescence (HTRF) binding assay. Thus, PD-1/PD-L1 inhibitor 1 might potentially be used for the treatment of cancer as well as infectious diseases, such as hepatitis C [2].

PD-1/PD-L1 inhibitor 1 +LPS treatment decreased PD-1 mRNA and protein expression in MH-S cells. BMS-1 treatment reduced TNF in LPS induced MH-S cells- α、 IL-1 β and IL-6, while IL-10 increased significantly. PD-1/PD-L1 inhibitor 1 pathway has anti apoptotic and anti-inflammatory effects on LPS stimulated MH-S cells[3].

PD-1/PD-L1 inhibitor 1 is a small molecule inhibitor of PD-1 delivered by coated patch. After 14 days, the new intima in the PD-1/PD-L1 inhibitor 1 coated patch was thinner than the control patch. In addition, compared with the control patch, the number of PD-1, CD3, CD68, CD45 and PCNA positive cells in the PD-1/PD-L1 inhibitor 1 coated patch was also significantly reduced, with a similar number of cut caspase control and three positive cells in the PD-1/PD-L1 inhibitor 1 coated patch. These data confirm that inhibition of PD-1 can reduce the thickness of new intima and the accumulation of inflammatory cells in the new intima formed after patch angioplasty (day 14) in rats[4].

GC15142

The factors that lead to resistance to PD-1 blockade include PD-L1 expression, tumor neoantigens expression and presentation, cellular signaling pathways (PI3K, WNT, IFN-γ, MAPK), tumor microenvironment (TME) (exhausted T cell, Treg, MDSC, TAM, other chemokines), and related immune genes (IPRES). The inhibitors against target molecules are indicated, which could enhance antitumor responses in in mouse models when combined with PD-1/PD-L1 blockade[1].

References:
[1] Bai J , Gao Z , Li X , et al. Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PDL1 blockade[J]. Oncotarget, 2017, 8(66).
[2] https://www. google.com/patents/WO2015034820A1
[3] Jia L, Liu K, Fei T, et al. Programmed cell death‑1/programmed cell death‑ligand 1 inhibitors exert antiapoptosis and antiinflammatory activity in lipopolysaccharide stimulated murine alveolar macrophages[J]. Experimental and Therapeutic Medicine, 2021, 21(4): 1-7.
[4] Bai H, Wang Z, Li M, et al. Inhibition of programmed death‐1 decreases neointimal hyperplasia after patch angioplasty[J]. Journal of Biomedical Materials Research Part B: Applied Biomaterials, 2021, 109(2): 269-278.

Chemical Properties

Cas No. 1675201-83-8 SDF
Synonyms BMS-1, Programmed Cell Death 1/Programmed Cell Death-Ligand 1 Inhibitor 1
Chemical Name (S)-1-(2,6-dimethoxy-4-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)benzyl)piperidine-2-carboxylic acid
Canonical SMILES O=C([C@H]1N(CC2=C(OC)C=C(OCC3=CC=CC(C4=CC=CC=C4)=C3C)C=C2OC)CCCC1)O
Formula C29H33NO5 M.Wt 475.58
Solubility ≥ 5.98mg/mL in DMSO with ultrasonic and warming Storage Store at -20°C
General tips Please select the appropriate solvent to prepare the stock solution according to the solubility of the product in different solvents; once the solution is prepared, please store it in separate packages to avoid product failure caused by repeated freezing and thawing.Storage method and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored at -20°C, please use it within 1 month.
To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time.
Shipping Condition Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request.

Complete Stock Solution Preparation Table

Prepare stock solution
1 mg 5 mg 10 mg
1 mM 2.1027 mL 10.5135 mL 21.027 mL
5 mM 0.4205 mL 2.1027 mL 4.2054 mL
10 mM 0.2103 mL 1.0513 mL 2.1027 mL
  • Molarity Calculator

  • Dilution Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
**When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / CoA (available online).

Calculate

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.

Reviews

Review for PD-1/PD-L1 inhibitor 1 (BMS-1)

Average Rating: 5 ★★★★★ (Based on Reviews and 38 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for PD-1/PD-L1 inhibitor 1 (BMS-1)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.